


FIGURE 1

1 2 3 4 5 6 7 8



β -actin

FIGURE 2

1 2 3 4 5



IL-10



FIGURE 3




FIGURE 4





FIGURE 5A

1 2 3 4 5



FIGURE 5B

1 2 3 4 5



80Kd----

34Kd----




FIGURE 6




FIGURE 7

	Leader -----	
RAT	ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T-----G-----	67
HUM	-----GA-----TG-C-----CT-----T-----G-T-----T-----G-----	55
	V-like domain -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----	189
RAT	AAAGCCGTAGGCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTTCAGCCCACCT	268
MOU	-----GA-----C-----A-----A-C-----TG-----	268
HUM	-----T-----A-----C-T-----G-GAA-----G-G-C-----TG-----	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG-----A-----G-----T-----CA	335
HUM	-T-G-----A-----T-CC-----C-A--T--C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA-----GA-C-----C-----T-----CA-----A-A--	402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G	390
	C-like domain -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C-CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTGAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG--T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	--A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--	591
RAT	AAAGACCCCAAACCTCAGGTGGAAAGGAAGTGATCTGCCAGGTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC--	658
	Transmembrane region -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T-----A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--	725
	Cytoplasmic region -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C--C-A-----A-----C-G-----T-----G-----C-A--	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	--A-----	837
HUM	---TG-----AG-T-----A-----C-----	825

FIGURE 8

Leader sequence-----

-30 -1

RAT M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A

MOU -----L-----I---G-----

HUM - I - M - - - S - - - - V - - V M - - - - V - - C - - -

|V-like domain (domain I) -----

RAT Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L

MOU -----A-----S-----

HUM - - - - Q - - - - - E - - - Y - - - - K - - - - Q N A - - - A - -

31 ..

RAT I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y

MOU -----S-----T-----A-----

HUM -----E N-----

61

RAT K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M

MOU -----V-----W--S-----H I G-----

HUM - - - - K - - - - Q - - - - Q - - - - T - - - - I - - - - E - - - -

91* .. |C-like domain (domain II)-----

RAT C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N

MOU -----T-----Q-----

HUM -----F G - - I - - - - V - - - - S - - - - K

121 .. .

RAT Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E

MOU -----T-----T-----

HUM F S - - - - - M V F - - - - V P R - - - -

151**

RAT N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K

MOU -----F-----

HUM - - - - V T L S - - P - - - - H I - - - - N - - - -

181 . |Transmembrane region -----

RAT E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L

MOU -----

HUM -----H-----T--T--F-----T V N-----Y-----

211 |Cytoplasmic region -----

RAT L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S

MOU -----I-----

HUM -----V-----D-----L

241


RAT S Q G M Q R M K

MOU -----

HUM - - - - V - - K - - - T

* invariant cysteine residues: ** invariant asparagine (N-linked oligosaccharides)

FIGURE 9



CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

FIGURE 10





FIGURE 11



NPC from Flt3 treated mice

FIGURE 12




FIGURE 13





FIGURE 14



NPC cells infused into renal transplant recipients

FIGURE 15





FIGURE 16



Monoclonal antibodies added to culture





FIGURE 17



Monoclonal antibodies added to culture

FIGURE 18A





FIGURE 18B



FOOT "451660

THESE
FIGURE 19

**Effect of anti-OX2 on
spontaneous abortions**





FIGURE 20

Effect of OX2:Fc on spontaneous abortions or renal allograft rejection

CBA with C57BL/6 grafts



Day of infusion/no. doses of OX2:Fc




FIGURE 21

1




FGL 2

2



3



OX-2





FIGURE 22

EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)



FOOTHESE

FIGURE 23

EXPRESSION OF OX-2 ON CYTOKERATIN-POSITIVE CELLS (TROPHOBLAST)

